Published in Front Cardiovasc Med on July 14, 2015
Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran. Drug Des Devel Ther (2016) 0.75
VKORC1 and CYP2C9 polymorphisms related to adverse events in case-control cohort of anticoagulated patients. Medicine (Baltimore) (2016) 0.75
Anticoagulation increases alveolar hemorrhage in mice infected with influenza A. Physiol Rep (2016) 0.75
Hypereosinophilic syndrome presenting with multiple organ infiltration and deep venous thrombosis: A case report and literature review. Medicine (Baltimore) (2016) 0.75
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med (2012) 11.86
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med (2003) 11.00
Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med (2010) 9.92
Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med (2009) 9.17
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med (2013) 7.76
Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med (2013) 7.00
2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J (2014) 6.32
Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.88
Is laboratory monitoring of low-molecular-weight heparin therapy necessary? Yes. J Thromb Haemost (2004) 4.97
A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med (1995) 4.71
Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med (2004) 4.52
Prognosis of cancers associated with venous thromboembolism. N Engl J Med (2000) 4.51
Apixaban for extended treatment of venous thromboembolism. N Engl J Med (2012) 4.37
Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost (2007) 4.09
Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med (2002) 3.83
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood (2002) 3.59
Deep vein thrombosis. Lancet (2005) 3.43
Risk assessment for recurrent venous thrombosis. Lancet (2010) 3.31
Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J (2006) 3.05
Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA (2005) 3.04
Pulmonary embolism and deep vein thrombosis. Lancet (2012) 2.97
Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet (2003) 2.81
Is laboratory monitoring of low-molecular-weight heparin therapy necessary? No. J Thromb Haemost (2004) 2.68
Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost (2008) 2.60
Derivation and validation of a prognostic model for pulmonary embolism. Am J Respir Crit Care Med (2005) 2.51
Massive pulmonary embolism. Circulation (2006) 2.27
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost (2013) 2.24
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J (2013) 2.21
Probability of recurrence of thrombosis in patients with and without factor V Leiden. Thromb Haemost (1996) 2.07
Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation (2010) 2.05
The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med (1999) 1.97
Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost (2014) 1.92
Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med (2006) 1.88
Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood (2014) 1.86
Outcomes and predictors of very stable INR control during chronic anticoagulation therapy. Blood (2009) 1.84
Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med (2000) 1.81
Vitamin K antagonists and pregnancy outcome. A multi-centre prospective study. Thromb Haemost (2006) 1.67
Epidemiology of stroke in Innherred, Norway, 1994 to 1996. Incidence and 30-day case-fatality rate. Stroke (1997) 1.58
Trends in incidence and case fatality rates of acute myocardial infarction in Denmark and Sweden. Heart (2003) 1.52
Risk factors for venous thrombotic disease. Thromb Haemost (1999) 1.48
Prospective validation of the Pulmonary Embolism Severity Index. A clinical prognostic model for pulmonary embolism. Thromb Haemost (2008) 1.36
Investigation and management of heritable thrombophilia. Br J Haematol (2001) 1.32
Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. J Clin Oncol (2015) 1.15
Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor. J Thromb Haemost (2004) 1.14
Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism. Cochrane Database Syst Rev (2006) 1.13
Venous thromboembolism in very elderly patients: findings from a prospective registry (RIETE). Haematologica (2006) 0.99
The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost (1997) 0.95
Risk factors for venous thromboembolism in cancer: novel findings from the Vienna Cancer and Thrombosis Study (CATS). Thromb Res (2014) 0.94
Comparison of two prognostic models for acute pulmonary embolism: clinical vs. right ventricular dysfunction-guided approach. J Thromb Haemost (2011) 0.92
The risk of recurrent venous thromboembolism among heterozygous carriers of the G20210A prothrombin gene mutation. Br J Haematol (2001) 0.92
High prevalence of asymptomatic deep vein thrombosis on admission in a medical unit among elderly patients. Thromb Haemost (2002) 0.91
The validation and reproducibility of the pulmonary embolism severity index. J Thromb Haemost (2010) 0.88
The management of thrombosis in pregnancy: role of low-molecular-weight heparin. Thromb Haemost (2007) 0.85
Trends in acute myocardial infarction prognosis and treatment in southwestern France between 1985 and 1990 (the MONICA Project-Toulouse). Am J Cardiol (1995) 0.84
Treatment of venous thromboembolism. J Thromb Haemost (2005) 0.82
[2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism]. Kardiol Pol (2014) 0.81
Anticoagulation in patients with impaired renal function and with haemodialysis. Anticoagulant effects, efficacy, safety, therapeutic options. Hamostaseologie (2014) 0.76
Risk of venous thromboembolism and primary prophylaxis in cancer. Should all patients receive thromboprophylaxis? Hamostaseologie (2011) 0.76